Asty will behave like a Classic spinoff stock for a while, unknown, deserted, dismissed and with wide swings, especially due to the fact there are no revenues.
Until either the market warms up to the sector Probably after some one gets good Phase II, III, or it starts Phase 3 itself.
It has not only great IP, but some great products in clinical trials. It will take some while, but if even one product makes if through, the sky is the limit.
News 
Market Data 
Discover 
